Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Abstract Text:

Evgeny M Krupitsky,Anatoly A Rudenko,Andrey M Burakov,Tatyana Y Slavina,Alexander A Grinenko,Brian Pittman,Ralitza Gueorguieva,Ismene L Petrakis,Edwin E Zvartau,John H Krystal,

BACKGROUND: Benzodiazepines are the standard pharmacotherapies for ethanol detoxification, but concerns about their abuse potential and negative effects upon the transition to alcohol abstinence drive the search for new treatments. Glutamatergic activation and glutamate receptor up-regulation contribute to ethanol dependence and withdrawal. This study compared 3 antiglutamatergic strategies for ethanol detoxification with placebo and to the benzodiazepine, diazepam: the glutamate release inhibitor, lamotrigine; the N-methyl-D-aspartate glutamate receptor antagonist, memantine; and the AMPA/kainite receptor inhibitor, topiramate. METHODS: This placebo-controlled randomized single-blinded psychopharmacology trial studied male alcohol-dependent inpatients (n=127) with clinically significant alcohol withdrawal symptoms. Subjects were assigned to 1 of 5 treatments for 7 days: placebo, diazepam 10 mg TID, lamotrigine 25 mg QID, memantine 10 mg TID, or topiramate 25 mg QID. Additional diazepam was administered when the assigned medication failed to suppress withdrawal symptoms adequately. RESULTS: All active medications significantly reduced observer-rated and self-rated withdrawal severity, dysphoric mood, and supplementary diazepam administration compared with placebo. The active medications did not differ from diazepam. CONCLUSIONS: This study provides the first systematic clinical evidence supporting the efficacy of a number of antiglutamatergic approaches for treating alcohol withdrawal symptoms. These data support the hypothesis that glutamatergic activation contributes to human alcohol withdrawal. Definitive studies of each of these medications are now needed to further evaluate their effectiveness in treating alcohol withdrawal.

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Publishing Authors By Initials

EM Krupitsky,AA Rudenko,AM Burakov,TY Slavina,AA Grinenko,B Pittman,R Gueorguieva,IL Petrakis,EE Zvartau,JH Krystal,

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: triazines research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: triazines research

PUBMED ID PMID:

MEDLINE DATE:

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Alcoholism, clinical and experimental research

VOLUME: 31

Page Numbers: 604-11

Journal Abbreviation: Alcohol. Clin. Exp. Res.

ISSN: 0145-6008

DAY: 3

MONTH: Apr

YEAR: 2007

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7707242

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Keywords Mesh Terms:

KEYWORDS: Triazines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Information

Substance Name: topiramate

Registry Number: 97240-79-4

Grant and Affiliation Information for Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.

AFFILIATION: St. Petersburg Regional Center of Addictions and Psychopharmacology, Pavlov State Medical University, St. Petersburg, Russia.

Country: England

AGENCY: United States NIAAA

GRANT: R21-AA014543-01A1

ACRONYM: AA

MEDLINETA: Alcohol Clin Exp Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam Related Publications

• Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
• Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
• Biochemical Analysis of HIV-1 Integrase Variants Resistant to Strand Transfer Inhibitors.
• Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
• Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report.
• Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients.
• Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia.
• IgE-Induced Mast Cell Survival Requires the Prolonged Generation of Reactive Oxygen Species.
• MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases.
• Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar.
• Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy.
• Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders.
• Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
• Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation.
• Psychomotor performance deficits and their relation to prior nights' sleep among individuals with primary insomnia.
• Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent.
• Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
• The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.